Oramed Pharmaceuticals (ORMP) Short-term Investments (2011 - 2026)

Oramed Pharmaceuticals has reported Short-term Investments for 16 years, with the latest figure at $5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 80.7% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (down 80.7% YoY), and the FY2025 full-year result was $5.4 million, down 90.2% from the prior year.
• Short-term Investments for Q1 2026 stood at $5.0 million, down from $5.4 million in the prior quarter.
• The five-year high for Short-term Investments was $121.1 million in Q3 2022, with the low at $366000.0 in Q1 2023.
• Historically, Short-term Investments has averaged $50.5 million across 5 years, with a median of $42.7 million in 2024.
• Annual changes were most pronounced in 2023 — Short-term Investments sank 99.66% — and 2024, when it soared 21835.79%.
• Oramed Pharmaceuticals' Short-term Investments stood at $3.7 million in 2022, then soared by 2445.52% to $95.3 million in 2023, then plunged by 41.98% to $55.3 million in 2024, then sank by 90.2% to $5.4 million in 2025, then retreated by 8.34% to $5.0 million in 2026.
• The last three Short-term Investments figures came in at $5.0 million (Q1 2026), $5.4 million (Q4 2025), and $73.5 million (Q3 2025), per Business Quant data.